A5080724574- Epilepsy research and treatment
- Alzheimer's disease research and treatments
- Thyroid and Parathyroid Surgery
- Pharmacological Effects and Toxicity Studies
- Traumatic Brain Injury Research
- Genetic Syndromes and Imprinting
- Neurofibromatosis and Schwannoma Cases
- Parathyroid Disorders and Treatments
- Long-Term Effects of COVID-19
- Mitochondrial Function and Pathology
- Dementia and Cognitive Impairment Research
- Diet and metabolism studies
- Infectious Encephalopathies and Encephalitis
- Glycogen Storage Diseases and Myoclonus
- Neurological disorders and treatments
University of Oxford
2021-2024
Oxford Research Group
2024
John Radcliffe Hospital
2024
University College London
2015-2017
National Hospital for Neurology and Neurosurgery
2015-2016
See Bernasconi (doi:10.1093/aww202) for a scientific commentary on this article. Temporal lobe epilepsy, the most prevalent form of chronic focal is associated with high prevalence cognitive impairment but responsible underlying pathological mechanisms are unknown. Tau, microtubule-associated protein, hallmark several neurodegenerative diseases including Alzheimer's disease and traumatic encephalopathy. We hypothesized that hyperphosphorylated tau pathology decline in temporal epilepsy...
To characterize the experience of people with epilepsy and aligned healthcare workers (HCWs) during first 18 months COVID-19 pandemic compare experiences in high-income countries (HICs) non-HICs.
Abstract: Based on original descriptions of brain calcification by Theodor Fahr, calcification, and more specifically basal ganglia is referred to as Fahr's syndrome. Recent identification genetic mutations has concerted the description this erstwhile heterogeneous condition which we refer here disease. disease refers idiopathic without a secondary (non-genetic) cause. Idiopathic (IBGC) another term, offers accurate condition. Within last 2 years, for IBGC have been described in SLC20A2 ,...
Abstract Objective To assess whether the antiseizure medication levetiracetam may improve cognition in individuals with Alzheimer's disease who have not previously experienced a seizure. Methods We performed randomized, double‐blind, placebo‐controlled crossover pilot study mild‐to‐moderate disease. Electroencephalography was at baseline and those active epileptiform discharges were excluded. Eligible participants randomized to placebo for 12 weeks or an arm of oral (4 up‐titration 500 mg...
Abstract Objective To assess whether the antiseizure medication levetiracetam may improve cognition in individuals with Alzheimer’s disease who have not previously experienced a seizure. Methods We performed randomised, double-blind, placebo-controlled crossover study mild-to-moderate disease. Electroencephalography was at baseline and those active epileptiform discharges were excluded. Eligible participants randomised to placebo for 12 weeks or an arm of oral (4 up-titration 500 mg twice...
Abstract Background The increasingly appreciated intersection between epilepsy and Alzheimer’s disease offers potential therapeutic opportunity. We therefore initiated a pragmatic pilot study to explore whether the anti‐seizure medication levetiracetam might offer benefit people with disease. Methods Investigation of Levetiracetam in Disease (ILiAD) trial is randomised, double‐blind, placebo‐controlled trial. ILiAD recruits mild moderate who have not previously had seizure whom routine...
Abstract Background: Although Alzheimer’s disease affects around 800,000 people in the UK and costs almost £23 billion per year, currently licensed treatments only offer modest benefit at best. Seizures, which are more common patients with than age matched controls, may contribute to loss of nerve cells abnormal brain discharges can disrupt cognition. This aberrant electrical activity therefore present potentially important drug targets.The anti-epileptic levetiracetam reduce cortical...